Conjuchem, Inc.

Conjuchem Biotechnologies Inc.

Nissab Boudjellab

Dominique P Bridon

Martin Robitaille

Karen Thibaudeau

Peter G Milner

Roger Léger

Julie Carette

Alan M Ezrin

Dominique Bridon

Roger Leger

Lucie Jetté

Dominique Blanchard

Robert P Dufresne

Corinne Benquet

Margaret Hardy

Robert R Dufresne

This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.

Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders

Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.

Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.

Long lasting growth hormone releasing factor derivatives

This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.

Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders

Long lasting fusion peptide inhibitors of viral infection

Antibodies to a therapeutic agent and its derivatives and conjugates are disclosed, including antibodies to argatroban and its derivatives and conjugates. The antibodies are useful as reagents in assays and diagnostic kits for determining the concentration of a therapeutic agent or its derivatives and conjugates in biological samples, and further have therapeutic uses in treatment for potential toxicity associated with stable therapeutic conjugates and derivatives, both in vivo and ex vivo.

Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments

Growing community of inventors

Dorval, Canada

Nissab Boudjellab